Abstract: FR-PO0674
Efficacy of SGLT2 Inhibition in Patients with Immune Glomerulopathy
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - ANCA/FSGS
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Cheng, Hong, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Ye, Nan, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Shi, Yunqi, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
- Wang, Guoqin, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
Background
In guidelines, sodium-glucose cotransporter 2 inhibitors (SGLT2is) have become the cornerstone of treatment in patients with chronic kidney disease (CKD). The main mechanism is to reduce glomerular hyperfiltration by blocking the reabsorption of sodium and glucose in the proximal tubules. However, the progression of immune glomerulopathy is mainly related to glomerular damage caused by inflammation, immune dysregulation and other factors. To date, the efficacy of SGLT2is in immune glomerulopathy, especially in patients without glomerular hyperfiltration, has not been clearly elaborated by sufficient trials.
Methods
Adult patients diagnosed with biopsy-proven immune glomerulopathy at Beijing Anzhen Hospital, and received at least 3 months of SGLT2is treatment were included in this study. Patients with diabetic nephropathy were excluded. Baseline and follow-up data were extracted from medical records retrospectively. Longitudinal repeated measures mixed-effects linear regression models were used to analyze changes of 24-hour proteinuria, albumin and estimated glomerular filtration rate (eGFR) over follow-up, and estimate mean differences from baseline to 3, 6, 9, 12 months. Additionally, a mixed-effects binomial logistic regression model was used to predict the achievement of a ≥30% proteinuria reduction from baseline during follow-up. The statistical analysis were performed using IBM SPSS Statistics 27.0.
Results
A total of 300 patients met the inclusion criteria. The geometric mean change of proteinuria from baseline was -22.63%, -40.15%, -53.69% and-64.17% after 3, 6, 9 and 12 months after initiation of SGLT2 inhibitor treatment, respectively. The change of serum albumin from baseline was 2.96%, 6.00%, 9.14% and 12.36% at 3, 6, 9 and 12 months, while eGFR changed by 0.90%, -1.79%, -2.67%, and-3.54%. By mixed-effects logistic model, baseline serum albumin emerged as a predictor of a ≥30% proteinuria reduction (odds ratio 0.97, 95% CI 0.95-0.99, P =0.002). However, patients with glomerular hypertrophy only have a possible trend of decreasing proteinuria by ≥30% compared with those without glomerular hypertrophy (odds ratio 1.08, 95% CI 0.76-1.54, P =0.652).
Conclusion
SGLT2is reduced proteinuria and increased serum albumin in patients with immune glomerulopathy from 3 months after initiation of treatment. Patients with lower baseline serum albumin were more likely to achieve a ≥30% proteinuria reduction.